| __timestamp | Dr. Reddy's Laboratories Limited | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 56369000000 | 16768000000 |
| Thursday, January 1, 2015 | 62786000000 | 14934000000 |
| Friday, January 1, 2016 | 62427000000 | 13891000000 |
| Sunday, January 1, 2017 | 62453000000 | 12775000000 |
| Monday, January 1, 2018 | 65724000000 | 13509000000 |
| Tuesday, January 1, 2019 | 70421000000 | 14112000000 |
| Wednesday, January 1, 2020 | 80591000000 | 13618000000 |
| Friday, January 1, 2021 | 86645000000 | 13626000000 |
| Saturday, January 1, 2022 | 100551000000 | 17411000000 |
| Sunday, January 1, 2023 | 42907000000 | 16126000000 |
| Monday, January 1, 2024 | 115557000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outpaced Merck & Co., Inc. in terms of cost of revenue. From 2014 to 2023, Dr. Reddy's saw a significant increase of approximately 105% in their cost of revenue, peaking in 2024. In contrast, Merck's cost of revenue remained relatively stable, with a slight increase of around 4% over the same period. Notably, Dr. Reddy's experienced a dramatic drop in 2023, highlighting potential operational challenges. This comparison underscores the dynamic nature of the pharmaceutical sector, where strategic financial management is key to sustaining growth and competitiveness. As we look to the future, these trends offer valuable insights into the operational efficiencies and market strategies of these industry giants.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Dr. Reddy's Laboratories Limited
Cost of Revenue Comparison: Johnson & Johnson vs Dr. Reddy's Laboratories Limited
Cost of Revenue Comparison: Merck & Co., Inc. vs BeiGene, Ltd.
Analyzing Cost of Revenue: Merck & Co., Inc. and Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and PTC Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Merck & Co., Inc. and Mesoblast Limited
Comparing Cost of Revenue Efficiency: GSK plc vs Dr. Reddy's Laboratories Limited
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
Biogen Inc. vs Dr. Reddy's Laboratories Limited: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Bio-Techne Corporation
Cost Insights: Breaking Down Dr. Reddy's Laboratories Limited and ACADIA Pharmaceuticals Inc.'s Expenses
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and Dyne Therapeutics, Inc.